Latest Breaking News On - Operational experience - Page 6 : comparemela.com

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced the appointment of Ms. Kathryn Gregory as Vice President and Head of Corporate Business Development, reporting to Mr. John F. Chin, Chief Business Officer of Antengene. In this role, Kathryn will be responsible for leading external business development including in/out-licensing, co-development/commercialization, mergers and acquisitions, and other collaboration agreements supporting Antengene's objectives.

United statesJohnf chinJay meiKathryn gregoryAsia pacificSeneb biosciencesKg biopharma consultingUniversity of californiaAntengene corporationCalithera biosciences incAntengene corporation limitedPepperdine universityChief business officerCalithera biosciencesNew drug applicationsCorporation limited